Esperion Hosting Virtual Research & Development Day
27 oct. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
19 oct. 2022 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on October 18, 2022, the Compensation Committee of Esperion’s Board of Directors granted 5 new...
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
17 oct. 2022 08h02 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion to Participate in Upcoming September Investor Conferences
30 août 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare...
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
26 août 2022 08h16 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04 août 2022 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
02 août 2022 07h00 HE
|
Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
25 juil. 2022 15h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB...
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
12 juil. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on...
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
03 juin 2022 12h30 HE
|
Esperion Therapeutics, Inc.
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE...